



EANM FOCUS

MOLECULAR IMAGING
OF DEMENTIA -
THE FUTURE IS HERE



JANUARY 31 - FEBRUARY 2, 2019
CANNES, FRANCE

focusmeeting.eanm.org

Track

1



Thursday, January 31, 2019
09:00 – 13:00

PET as Part of the Biomarker Toolbox for Early Clinical Diagnosis of Alzheimer Disease (AD)

Chairpersons: J. Arbizu, V. Garibotto,
P. Scheltens, S. Minoshima

- 09:00 – 09:20 **Unmet Need for Early Diagnosis of Prodromal AD**
B. Dubois
-
- 09:25 – 09:45 **Contribution of MRI for Early Diagnosis of AD**
G. Frisoni
-
- 09:50 – 10:10 **Contribution of CSF for Early Diagnosis of AD**
H. Zetterberg
-
- 10:15 – 10:35 **Contribution of PET for Early Diagnosis of AD**
S. Minoshima
-
- 11:00 – 11:10 **Controversy: Early Diagnosis of AD – PET in the Initial Work-Up**
J. Arbizu
-
- 11:10 – 11:35 **Controversy: In Favour**
F. Nobili
-
- 11:40 – 12:05 **Controversy: Against**
P. Scheltens
-
- 12:05 – 12:15 **Questions & Answers**
-
- 12:15 – 13:00 **Consensus on Imaging for Early Diagnosis of AD**
S. Minoshima, J. Arbizu, V. Garibotto



Track

2

Thursday, January 31, 2019
14:00 – 18:00

Molecular Imaging in the Differential Diagnosis of Dementia

Chairpersons: S. Morbelli, J. Arbizu

- 14:00 – 14:25 Contribution of MRI
F. Agosta
-
- 14:30 – 14:55 Unmet Clinical Needs and Contribution of PET in Frontotemporal Lobar Degeneration
G. Rabinovici
-
- 15:00 – 15:25 Unmet Clinical Needs and Contribution of Molecular Imaging in Parkinsonian Syndromes
D. Brooks
-
- 16:00 – 16:10 Controversy: FDG-First versus Amyloid-First for Differential Dementia Diagnosis?
J. Arbizu
-
- 16:15 – 16:35 Controversy: FDG PET-First
D. Perani
-
- 16:40 – 17:00 Controversy: Amyloid PET-First
O. Sabri
-
- 17:00 – 17:10 Questions & Answers
-
- 17:10 – 18:00 Consensus on Molecular Imaging for Differential Dementia Diagnosis
J. Arbizu, S. Morbelli



Track

3

Friday, February 1, 2019
09:00 – 13:00

Clinical Acceptance of Amyloid Imaging

Chairpersons: V. Garibotto, A. Drzezga

- 09:00 – 09:20 **The Current Status of Amyloid Markers (PET and CSF) Reimbursement**
A. Nordberg
-
- ROUND TABLE: Evidence for a Routine Use of Amyloid Markers**
- 09:25 – 09:45 **The Point of View of the Scientific Community**
S. Landau
-
- 09:50 – 10:10 **The Point of View of the Payers and the Industry in the IMI-2 Initiative**
G. Frisoni
-
- 10:15 – 10:35 **The Point of View of the Patients and the Families**
M. Carillo
-
- 11:00 – 11:20 **Ongoing Studies to Provide Answers: AMYPAD and Other European Initiatives**
F. Barkhof
-
- 11:25 – 11:45 **Ongoing Studies to Provide Answers: IDEAS and Other Collaborative Efforts Worldwide**
G. Rabinovici
-
- DISCUSSION AND CONSENSUS**
- 11:50 – 12:30 **Consensus on Clinical Use of Amyloid Markers**
A. Drzezga
-
- 12:30 – 13:00 **Consensus on Research Priorities**
V. Garibotto

4

Friday, February 1, 2019

14:00 – 18:00

The Use of PET in Dementia Research

Chairpersons: H. Barthel, G. Chételat, A. Drzezga

14:00 – 14:20 **Impact of Brain Connectivity and Reserve in Dementia**

G. Chételat

ROUND TABLE: The Complementarity of Neuroimaging Techniques in Clinical Trials
i) to Enrich Target Populations and
ii) to Monitor Drug Effects

14:25 – 14:45 **FDG-PET Imaging**

K. Herholz

14:50 – 15:10 **MR Imaging**

P. Scheltens

15:15 – 15:35 **Amyloid and Tau-PET Imaging**

V. Villemagne

16:00 – 16:10 **Controversy: Guidelines for Research Criteria in Preclinical AD: Should Amyloid be Considered as the Lead Biomarker in the Hierarchy?**

A. Drzezga

16:15 – 16:35 **Controversy: In Favour**

C. Jack

16:40 – 17:00 **Controversy: Against**

A. Fjell

17:00 – 17:35 **Consensus on Hierarchy of Biomarkers in Preclinical AD**

A. Drzezga

17:40 – 18:00 **Do We Need Multimodal Imaging?**

A. Drzezga



5

Saturday, February 2, 2019
09:00 – 13:00

New Developments and Methodology

Chairpersons: I. Law, E. van de Giessen, H. Barthel

- 09:00 – 09:20 **Imaging of Neuroinflammation in Neurodegeneration – What does it Add to Our Understanding?**
D. J. Brooks
-
- 09:25 – 09:45 **Principles of Absolute PET Quantification for Monitoring Longitudinal Treatment Response?**
A. Lammertsma
-
- 09:50 – 10:10 **Amyloid and Tau Imaging: Centiloid, Centaur, and Clinical Use**
V. Villemagne
-
- 10:15 – 10:35 **PET-Tau Imaging for Early and Differential Diagnosis of AD**
O. Hansson
-
- 11:00 – 11:20 **Standards for In-Vitro Validation of PET Tracers in Neurodegeneration**
A. Nordberg
-
- 11:25 – 11:55 **Hybrid PET/MRI: Has it Developed the Dementia Field?**
H. Barthel
-
- 12:00 – 12:20 **Issues in Quantification for Neurological PET Studies**
B. Hutton
-
- 12:25 – 13:00 **Discussion: What else do We Need for Progress? (New Tracers, Artificial Intelligence, etc.)**
I. Law, E. van de Giessen

We kindly thank our panelists
for their valuable support.



The aim of the meeting is to provide an in-depth overview and critical assessment of the latest development and future directions in the management of dementia, with a focus on the role of neuroimaging in general and nuclear medicine in particular. The goal is to arrive at a multidisciplinary consensus on the current state of the art and to make expert recommendations how to advance the field towards establishing clinical impact.

Registration Information

Early Registration Fee (until October 25, 2018) EUR 650.00

Late Registration Fee (from October 26, 2018) EUR 850.00

focusmeeting.eanm.org/registration/

Hotel Info

Novotel Cannes Montfleury
25 avenue Beauséjour
06400 Cannes, France

Price per room per night, including breakfast and VAT:

Double Single Use Standard (uphill view) EUR 99.00

Double Room Standard (uphill view) EUR 109.00

focusmeeting.eanm.org/hotel-booking/

We kindly thank the following companies
for their sponsorship engagement:

SIEMENS
Healthineers

Platinum Sponsor

Biogen

Gold Sponsor

Life *Molecular Imaging*

Gold Sponsor